in this issue
Pharma/Fine Chemicals Roundup – October 2
7:31 AM MDT | October 2, 2012 | By DEEPTI RAMESH
BASF to move pharma ingredients headquarters to US, appoints new business head
BASF says it will relocate the global headquarters of the pharma ingredients and services business unit from Evionnaz, Switzerland, to Florham Park, NJ. The company has also appointed Scott Thomson as the senior v.p. of the unit effective 1 October 2012. Thomson succeeds Martin Widmann, who will now head the fuel and lubricant solutions unit at Ludwigshafen. Prior to his new role, Thomson was v.p./market and customer development, North America at BASF at Florham Park.
Cedarburg Hauser expands API production capacity
Cedarburg Hauser Pharmaceuticals (CHP; Grafton, WI) says it has expanded the capacity of its active pharmaceutical ingredient (API) manufacturing plant in Wisconsin. CHP is a contract development and manufacturing organization, specializing in small-molecule APIs and pharmaceutical intermediates. The expansion is in response to an increased demand for contract manufacturing of commercial APIs and has been accompanied by additional upgrades aimed at improving safety and good manufacturing practice (GMP) systems, the company says.
Daiichi Sankyo to restructures pharma ingredient subsidiaries
Pharmaceutical company Daiichi Sankyo (Tokyo) says it has decided to reorganize three of its supply chain subsidiaries in Japan – Daiichi Sankyo Propharma (DSPP; Tokyo), Daiichi Sankyo Chemical Pharma (DSCP; Hiratsuka) and Daiichi Sankyo Logistics (DSLG; Tokyo) into two companies by April 2015, in order to build a competitive production system. Daiichi Sankyo currently utilizes DSPP for the production of active pharmaceutical ingredients (APIs) and dosage forms; DSCP for the production of APIs and intermediates, and DSLG for logistics. The two manufacturing plants of DSPP and DSCP at Odawara , Japan will also be integrated into one plant by April 2013, Daiichi Sankyo says. Through the reorganization of these three companies into two companies responsible for API production and dosage form/logistics by April 2015, each function will be enhanced and made structurally competitive on a global level, Daiichi Sankyo says. The Odawara plant of DSPP began operations in 1979. It mainly produces APIs and the plant employs about 140 people. The Odawara plant of DSCP started production in 1963. It mainly produces pharmaceutical intermediates and employs about 120 people.
Ashland to open pharmaceutical lab in Germany
Ashland says it will open a new pharmaceutical application laboratory at Düsseldorf in December 2012. The laboratory will provide technical support to Ashland’s European pharmaceutical and nutraceutical customers.
Lonza signs manufacturing deal with US biotech firm
Lonza says it has entered into a process transfer and manufacturing agreement with Celladon Corp. (San Diego, CA), a privately held biotechnology company focused on the discovery and development of treatments for cardiovascular diseases. Lonza, under the terms of the agreement, will manufacture cGMP-grade Mydicar, Celladon’s product candidate for the treatment of advanced heart failure, for use in future clinical trials. In the event Celladon intends to commence commercial scale manufacture of Mydicar, Celladon and Lonza have agreed to negotiate a commercial scale supply agreement, Lonza says.
Lonza to develop, manufacture U.S biopharma firm’s antibody drug conjugate
Lonza says that biopharmaceutical company Intellect Neurosciences (New York) has awarded the future development and manufacture of the antibody-drug conjugate Conjumab-A to Lonza, subject to completion of a definitive development and manufacturing agreement. Lonza will supply the preclinical study material for the drug optimization and drug selection for Intellect’s Conjumab-A, initially focusing on age-related macular degeneration (AMD) with potential applications for Alzheimer’s disease, Lonza says. Intellect is engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of proteinopathies.
Mitsubishi Gas Chemical exits coenzyme Q10 business
Mitsubishi Gas Chemical (MGC) says it will stop the manufacture and sale of coenzyme Q10, a material for pharmaceuticals and health food, due to poor profitability of the business. Production at MGC’s 70-m.t./year coenzyme Q10 production facility at Niigata, Japan will be discontinued at the end of March 2013. The coenzyme Q10 business of MGC, which was launched in 1980, has suffered losses in the recent past due to excessive supply from overseas manufacturers and increases in production capacity at MGC and other Japanese manufacturers, MGC says.